|
Casey Crawford Lynch, Managing Director
Casey Lynch works with companies to develop and implement strategic business plans and helps investors identify and profit from opportunities in neurotechnology. She is co-author of The Neurotechnology Industry Report, a comprehensive market analysis and strategic investment report on the brain industry and is the Managing Editor of Neurotech Insights, the neurotechnology investment newsletter. Casey is also on the Board of Directors of The Neurotechnology Industry Organization, a trade association for commercial neuroscience, and the co-founder and president of The Neurotechnology Development Foundation, a new non-profit formed to support translational research.
Previously, Casey was the co-founder and CEO of Aspira Biosystems, a venture backed drug discovery platform-company, which was acquired by Nanomune Inc. in 2004. Prior to the four years building Aspira, Casey oversaw toxicology screening and evaluated new product opportunities at Centaur Pharmaceuticals. There, she established disease model testing paradigms for multiple sclerosis, uveitis, and other neurological disorders.
Casey conducted primate preclinical trials for Alzheimer’s disease treatment at the Wadsworth Medical Center in Los Angeles and researched the neurological basis of schizophrenia and epilepsy at UCLA. Her graduate work on neurotrophic factor cell biology and neurodegenerative diseases was carried out in the Mobley lab at UCSF/ Stanford University and was funded by the NSF and an Alzheimer's Association Zenith Award. In addition to a BS in neuroscience from UCLA, she has an MS in neuroscience from UCSF and has completed the Management Development for Entrepreneurs (MDE) program of the Anderson School of Business.
|
|
Zack Lynch, Managing Director
Zack Lynch is the publisher of the investment newsletter, Neurotech Insights, editor of Brain Waves, an industry weblog providing commentary on the intersection of neuroscience and society, and co-author of NeuroInsights’ annual report on The Neurotechnology Industry. He is also the founder and Executive Director of the Neurotechnology Industry Organization, a trade association formed to provide a collective voice for the neurotech industry.
Zack is an economic and social forecaster advising global organizations on the impact of neurotechnology on business, government and society. Known for his scientific acumen and deep historical perspective, Mr. Lynch’s articles and vision have been sought out by diverse publications, including US News and World Report, Lancet Neurology, CMO Magazine, and the New York Academy of Sciences, among many others. Mr. Lynch serves on the advisory boards of McGovern Institute for Brain Research at MIT, the Center for Cognitive Liberty & Ethics, the Institute for Global Futures, and Socialtext, a software company.
Previously, he was an executive and founder of several enterprise software companies in profit optimization and collaborative forecasting. Zack received an MA in Economic Geography and double BS in Evolutionary Biology and Environmental Science, all from UCLA.
|
Frank Eeckman MD, PhD
Dr. Frank Eeckman is an analyst and consultant at NeuroInsights helping companies and investors identify and vet opportunities in neurotechnology. He writes indication and company features for Neurotech Insights, the neurotechnology industry newsletter published by NeuroInsights. He is the Director of Regulatory Policy at The Neurotechnology Industry Organization and co-founder and Chief Science Officer of Centient Biotech. Dr. Eeckman was an early innovator in the genomics revolution, leading Lawrence Berkeley National Laboratories’ bioinformatics team on the Human Genome Project. He has helped launch three biotech startups and headed discovery groups at Parke-Davis and Pfizer. He serves on the Scientific Advisory Board of several biotech companies, and provides investment analysis to venture capitalists and fund managers as well as consulting to both large and small companies.
Dr. Eeckman holds an MD cum laude from the University of Ghent Medical School, Belgium, where he was trained as a neurologist. He also earned a PhD in Neurophysiology at the University of California Berkeley, where he was a Fulbright Scholar.
|
|
